勃起功能障碍(ED)与高血压之间的关系是男科学研究的重点领域。目前研究认为,这两种疾病拥有相似的病理生理过程,如氧化应激效应造成血管内皮损害以及RhoA/Rho激酶活性上调。两种疾病均为血管功能损害这一病理过程的不同阶段。定期细致而全面评估高血压合并ED患者病情,并予以合理药物治疗显得尤为重要。在高血压患者中,5型磷酸二酯酶抑制剂无论是单用还是联合抗高血压药物使用都取得了令人满意的效果。目前,基因治疗以及脂肪源性干细胞治疗都展现出了良好的前景,通过转化医学方法可使其更好的为临床服务。
The relationship between erectile dysfunction (ED) and hypertension is a focus in andrological research. ED and hypertension share some pathophysiologic pathways, such as oxidative stress-induced endothelial dysfunction and up-regulated RhoA/Rho kinase activity, and both are the diseases at different stages of the pathological process of vascular dysfunction. Thus, it is particularly important to conduct regular and meticulous evaluation of such patients, so as to give rational individualized medication. Phosphodiesterase-5 inhibitors have an exceUent efficacy and safety profile in the management of hypertension, either used alone or with antihypertensive medication. At present, gene therapy and adipose-derived stem cell therapy have displayed favorable prospects in the management of ED and hypertension, and translational medicine may help bring more clinical benefits.